Coluracetam
Cas No.: 135463-81-9
What is coluracetam?
Coluracetam is a derivative of the nootropic preparation piracetam. The product also goes by the names BCI-540, MKC-231. Coluracetam was initially developed as an adjunctive drug for the treatment of Alzheimer’s disease. However, it turned out that the product also worked well as an antidepressant. In addition, the agent has proven to be an effective nootropic, which supports its use during periods of increased mental effort.
Use of Coluracetam
Coluracetam can be used to improve cognitive brain function. Increases concentration, helps to better focus attention. In addition, it can facilitate learning processes, memorization, information processing. It also turns out that the product has been used successfully in people suffering from depression, and this means that the symptoms of the disease can be alleviated.
The product can improve auditory and visual perception, in addition, it can raise energy and motivation levels, which translates into reduced physical and mental fatigue.
Mechanism of action
The effect of coluracetam is somewhat different from that of other racetams, derivatives of the parent compound, piracetam. This compound interacts with the high-affinity choline reuptake transporter HACU. In this way, the inhibitory effect of choline on the rate of acetylcholine synthesis is minimized. By increasing choline uptake and acting on AMPA receptors, coluracetam has a beneficial effect on brain function.
Coluracetam – dosage
The preparation is distinguished by its high bioavailability, the maximum concentration in the blood is reached after about 30 minutes, while the effect of the preparation lasts for about 3 hours. It is recommended to use a dose of 10 mg, and if the effect of the preparation is not satisfactory, then the dose can be gradually increased to 20, 30 or 40 mg.
For greater effectiveness, the product can be used in conjunction with Alpha GPC or cytocoline.
References:
- Takashina K, et al, MKC-231, a choline uptake enhancer: Mode of action of MKC-231 in the enhancement of high-affinity choline uptake. J Neural Transm., 2008 https://pubmed.ncbi.nlm.nih.gov/18461273/
- Shirayama Y, et al, Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats. Eur Neuropsychopharmacol, 2007 https://pubmed.ncbi.nlm.nih.gov/17467960/
- Akaike A, et al. “Protective effect of MKC-231, a novel high affinity choline uptake enhancer, on glutamate cytotoxicity in cultured cortical neurons.” Jpn J Pharmacol. 1998 Feb;76(2):219-22. https://www.sciencedirect.com/science/article/pii/S0021519819312326
- Bessho T, et al. “MKC-231, a choline-uptake enhancer: (1) long-lasting cognitive improvement after repeated administration in AF64A-treated rats.” J Neural Transm. (2008) https://link.springer.com/article/10.1007/s00702-008-0053-4
